HomeComparePMSNF vs PFE

PMSNF vs PFE: Dividend Comparison 2026

PMSNF yields 10000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PMSNF wins by $55137509079256512.00M in total portfolio value
10 years
PMSNF
PMSNF
● Live price
10000.00%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$55137509079256512.00M
Annual income
$54,073,795,673,722,890,000,000.00
Full PMSNF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — PMSNF vs PFE

📍 PMSNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPMSNFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PMSNF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PMSNF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PMSNF
Annual income on $10K today (after 15% tax)
$850,000.00/yr
After 10yr DRIP, annual income (after tax)
$45,962,726,322,664,450,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PMSNF beats the other by $45,962,726,322,664,450,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PMSNF + PFE for your $10,000?

PMSNF: 50%PFE: 50%
100% PFE50/50100% PMSNF
Portfolio after 10yr
$27568754539628256.00M
Annual income
$27,036,897,836,861,443,000,000.00/yr
Blended yield
98.07%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

PMSNF
No analyst data
Altman Z
-16.2
Piotroski
0/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PMSNF buys
0
PFE buys
0
No recent congressional trades found for PMSNF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPMSNFPFE
Forward yield10000.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$55137509079256512.00M$49.6K
Annual income after 10y$54,073,795,673,722,890,000,000.00$26,258.71
Total dividends collected$55066727460582336.00M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PMSNF vs PFE ($10,000, DRIP)

YearPMSNF PortfolioPMSNF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$1,010,700$1,000,000.00$9,153$693.39+$1.00MPMSNF
2$95,539,393$94,457,943.93$8,593$849.25+$95.53MPMSNF
3$8,447,007,736$8,344,780,585.66$8,336$1,066.78+$8447.00MPMSNF
4$698,565,746,383$689,527,448,105.17$8,437$1,384.80+$698565.74MPMSNF
5$54,040,711,670,213$53,293,246,321,583.74$9,013$1,875.40+$54040711.66MPMSNF
6$3,910,851,616,519,516$3,853,028,055,032,387.00$10,306$2,680.72+$3910851616.51MPMSNF
7$264,781,167,546,477,440$260,596,556,316,801,570.00$12,820$4,101.38+$264781167546.46MPMSNF
8$16,772,556,223,821,672,000$16,489,240,374,546,942,000.00$17,673$6,826.70+$16772556223821.65MPMSNF
9$994,124,678,068,810,000,000$976,178,042,909,320,800,000.00$27,543$12,591.86+$994124678068810.00MPMSNF
10$55,137,509,079,256,515,000,000$54,073,795,673,722,890,000,000.00$49,560$26,258.71+$55137509079256512.00MPMSNF

PMSNF vs PFE: Complete Analysis 2026

PMSNFStock

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive analysis of protein activity across regulatory and signaling pathways; TMT MS2 for analyzing cells and tissues when no phosphopeptide enrichment is required; and TMT MS3, a method for biomarker discovery in plasma and other complex samples where quantitative accuracy is the important factor. It also provides TMT Calibrator that analyzes diseased or treated tissue in parallel with peripheral fluids; TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates; and SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers. In addition, the company offers bioinformatics tools, including Proteome Discoverer for peptide sequence and TMT quantitation; SQuaT,CalDIT, and DIANA for normalized quantitative values and functional annotation at peptide and protein level; FeaST for visualization of data quality, class identifier model, and biomarker candidate lists; and FAT for identification of biological processes and cellular components showing variance. It primarily serves pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.

Full PMSNF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this PMSNF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PMSNF vs SCHDPMSNF vs JEPIPMSNF vs OPMSNF vs KOPMSNF vs MAINPMSNF vs JNJPMSNF vs MRKPMSNF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.